Patents by Inventor Michael John Martinelli

Michael John Martinelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Excitatory amino acid receptor antagonists
    Publication number: 20040082606
    Abstract: The present invention provides novel pharmaceutically acceptable salts of the compounds of Formula (I) and Formula (Ia), as well as methods for using the pharmaceutically acceptable salts, and also provides processes for making compounds of Formula (I) and Formula (Ia), or the pharmaceutically acceptable salts thereof. Compounds of formula (I) and formula (Ia) are useful for the treatment of neurological disorders, especially migraine.
    Type: Application
    Filed: June 13, 2003
    Publication date: April 29, 2004
    Inventors: Vien Van Khau, Michael Edward Letourneau, Michael John Martinelli
  • spla2 inhibitors
    Patent number: 6713505
    Abstract: A class of novel benzo(b)thiophene is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: March 30, 2004
    Assignee: Eli Lilly and Company
    Inventors: Michael Dean Kinnick, Ho-Shen Lin, Michael John Martinelli, John Michael Morin, Michael Enrico Richett
  • Novel spla2 inhibitors
    Publication number: 20030236232
    Abstract: A class of novel benzo(b)thiophene is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Application
    Filed: December 3, 2002
    Publication date: December 25, 2003
    Inventors: Michael Dean Kinnick, Ho-Shen Lin, Michael John Martinelli, John Michael Morin, Michael Enrico Richett
  • Glycoprotein llb/llla antagonists
    Publication number: 20030130342
    Abstract: This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Application
    Filed: September 9, 2002
    Publication date: July 10, 2003
    Inventors: Matthew J. Fisher, Anne Marie Happ, Joseph A. Jakubowski, Michael Dean Kinnick, Allen D. Kline, Michael John Martinelli, John Michael Morin, Michael Paal, Gerd Ruhter, Kenneth James Ruterbories, Daniel J. Sall, Theo Schotten, Marshall A. Skelton, Wolfgang Stenzel, Robert Theodore Vasileff
  • Selective iglur5 receptor antagonists
    Patent number: 6579886
    Abstract: The present invention provides compounds of formula (I): wherein W represents hydrogen, C1-C4 alkyl, —CH2CO2H, or CO2H; and X represents hydrogen, C1-C4 alkyl, —CH2CO2H, or CO2H; with the proviso that at least one of W or X must be other than hydrogen; or a prodrug or a pharmaceutically acceptable salt thereof; which are useful for treating migraine.
    Type: Grant
    Filed: September 3, 2002
    Date of Patent: June 17, 2003
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Michael Edward Le Tourneau, Michael John Martinelli, Mark Alan Winter
  • Selective iglur5 receptor antagonists
    Publication number: 20030055081
    Abstract: The present invention provides compounds of formula (I): wherein W represents hydrogen, C1-C4 alkyl, —CH2CO2H, or CO2H; and X represents hydrogen, C1-C4 alkyl, —CH2CO2H, or CO2H; with the proviso that at least one of W or X must be other than hydrogen; or a prodrug or a pharmaceutically acceptable salt thereof; which are useful for treating migraine.
    Type: Application
    Filed: September 3, 2002
    Publication date: March 20, 2003
    Inventors: Michael Gregory Bell, Michael Edward LeTourneau, Michael John Martinelli, Mark Alan Winter
  • Glycoprotein IIb/IIIa antagonists
    Patent number: 6448269
    Abstract: This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Grant
    Filed: June 18, 2001
    Date of Patent: September 10, 2002
    Assignee: Eli Lilly and Company
    Inventors: Matthew J. Fisher, Anne Marie Happ, Joseph A. Jakubowski, Michael Dean Kinnick, Allen D. Kline, Michael John Martinelli, John Michael Morin, Jr., Michael Paal, Gerd Rühter, Kenneth James Ruterbories, Daniel J. Sall, Theo Schotten, Marshall A. Skelton, Wolfgang Stenzel, Robert Theodore Vasileff
  • Bicyclic sPLA2 inhibitors
    Patent number: 6384041
    Abstract: The compounds are of the class of pyrrolo[2,3-d]pyrimidines useful for inhibiting sPLA2 mediated release of fatty acids for treatment of diseases such as septic shock.
    Type: Grant
    Filed: December 11, 2000
    Date of Patent: May 7, 2002
    Assignee: Eli Lilly and Company
    Inventors: Darrell Robert Hutchison, Michael John Martinelli, Thomas Michael Wilson
  • Process to prepare pharmaceutical compounds
    Patent number: 6252064
    Abstract: This invention provides a process for preparing diastereomerically pure cryptophycin compounds.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: June 26, 2001
    Assignees: Eli and Company, University of Hawaii, Wayne State University
    Inventors: Michael John Martinelli, Eric David Moher
  • Glycoprotein IIB IIIA antagonists
    Patent number: 6020362
    Abstract: This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Grant
    Filed: March 24, 1998
    Date of Patent: February 1, 2000
    Assignee: Eli Lilly and Company
    Inventors: Matthew J. Fisher, Anne Marie Happ, Joseph A. Jakubowski, Michael Dean Kinnick, Allen D. Kline, Michael John Martinelli, John Michael Morin, Jr., Michael Paal, Gerd Ruhter, Kenneth James Ruterbories, Daniel J. Sall, Theo Schotten, Marshall A. Skelton, Wolfgang Stenzel, Robert Theodore Vasileff
  • Process for preparing 4-substituted-1H-indole-3-glyoxamides
    Patent number: 5986106
    Abstract: A process for preparing 1H-indole-3-glyoxamides useful for inhibiting SPLA.sub.2 and novel intermediates useful in the preparation of such compounds.
    Type: Grant
    Filed: June 26, 1998
    Date of Patent: November 16, 1999
    Assignee: Eli Lilly and Company
    Inventors: Vien Van Khau, Michael John Martinelli, Joseph Matthew Pawlak
  • Glycoprotein IIb/IIIa antagonists
    Patent number: 5731324
    Abstract: This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Grant
    Filed: January 19, 1995
    Date of Patent: March 24, 1998
    Assignee: Eli Lilly and Company
    Inventors: Matthew J. Fisher, Anne Marie Happ, Joseph A. Jakubowski, Michael Dean Kinnick, Allen D. Kline, Michael John Martinelli, John Michael Morin, Jr., Michael Paal, Gerd Ruhter, Kenneth James Ruterbories, Daniel J. Sall, Theo Schotten, Marshall A. Skelton, Wolfgang Stenzel, Robert Theodore Vasileff